Canadian guidance explains hepatotoxicity evaluation of drugs in pre-market phase
This article was originally published in SRA
Executive Summary
Health Canada has issued final guidance on how manufacturers of pharmaceutical, biological and natural health products should evaluate the hepatotoxicity of their products in the pre-marketing phase of their product's development1.